产品
编 号：F760205
分子式：C24H29F2N5O3
分子量：473.52
分子式：C24H29F2N5O3
分子量：473.52
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 765914-60-1
产品详情
生物活性：
Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain.
体内研究：
Emprumapimod (ARRY-797) (30 mg/kg；口服) 在 SCID-beige 小鼠中抑制 IL-6 (91%) 和 TNF-α (95%) 的表达，在 RPMI-8226 异种移植物中抑制 p38 的磷酸化，在多发性骨髓瘤 (MM) 异种移植模型中抑制 RPMI-8226 肿瘤的生长 (72%)。Emprumapimod (30 mg/kg；口服；一天两次持续 4 周) 防止 LmnaH222P/H222P 小鼠左心室 (LV) 扩张和左心室缩短分数 (FS) 恶化。Animal Model:LmnaH222P/H222P mice were
Dosage:30 mg/kg
Administration:Administered orally by gavage starting when mice were 16 weeks of age and continuing until 20 weeks of age
Result:There were significant increases in LVEDD and LVESD as well as a decrease in FS, a parameter directly proportional to the LV ejection fraction.
体外研究：
Emprumapimod (ARRY-797) 抑制 LPS 诱导的 RPMI-8226 细胞产生 IL-6，IC50 值为 100 pM。
Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain.
体内研究：
Emprumapimod (ARRY-797) (30 mg/kg；口服) 在 SCID-beige 小鼠中抑制 IL-6 (91%) 和 TNF-α (95%) 的表达，在 RPMI-8226 异种移植物中抑制 p38 的磷酸化，在多发性骨髓瘤 (MM) 异种移植模型中抑制 RPMI-8226 肿瘤的生长 (72%)。Emprumapimod (30 mg/kg；口服；一天两次持续 4 周) 防止 LmnaH222P/H222P 小鼠左心室 (LV) 扩张和左心室缩短分数 (FS) 恶化。Animal Model:LmnaH222P/H222P mice were
Dosage:30 mg/kg
Administration:Administered orally by gavage starting when mice were 16 weeks of age and continuing until 20 weeks of age
Result:There were significant increases in LVEDD and LVESD as well as a decrease in FS, a parameter directly proportional to the LV ejection fraction.
体外研究：
Emprumapimod (ARRY-797) 抑制 LPS 诱导的 RPMI-8226 细胞产生 IL-6，IC50 值为 100 pM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备